Abiopharma

🔍 KIDRON NADAV (Director)

Company: ORAMED PHARMACEUTICALS INC. (ORMP)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 232,640 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,919,238.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 327,000 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,246,238.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: H | nature_of_ownership: By wholly-owned corporation | shares_owned_after: 126,000.00
• Acquired 109,000 shares of Performance Stock Units (Derivative)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 109,000.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3

Footnotes:

• F1: Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
• F2: Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
• F3: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.